News | May 09, 2026
Lonza surges on biologics boom
Expands manufacturing push & locks in major growth deals
Expands manufacturing push & locks in major growth deals
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
Approval strengthens the company’s growing international anti-infective portfolio
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Lifts full-year outlook as obesity drug boom accelerates
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Subscribe To Our Newsletter & Stay Updated
